A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus
Latest Information Update: 28 Apr 2026
At a glance
- Drugs Afimetoran (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 15 Apr 2026 According to Beeline Medicines Corporation media release, this Phase 2 study in SLE is ongoing and expected to complete in the second half of 2026, after which Beeline Medicines intends to commence its pivotal development program.
- 10 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 10 May 2024 Planned End Date changed from 15 May 2026 to 22 Apr 2029.